Skip to main content
Clinical Trials/NCT07364578
NCT07364578
Recruiting
Phase 3

Evaluating the Efficacy of Probiotic Supplements on Osteoarthritis Patients

Beni-Suef University1 site in 1 country146 target enrollmentStarted: February 15, 2025Last updated:

Overview

Phase
Phase 3
Status
Recruiting
Enrollment
146
Locations
1
Primary Endpoint
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

Overview

Brief Summary

The current study aims to evaluate the effectiveness of adding probiotics to the standard of care in improving OA patient-related outcomes such as pain, stiffness, and physical activity.

Detailed Description

Osteoarthritis (OA) is a severe progressive chronic arthropathy causing articular remodeling and inflammation of synovial tissue. The disease involves the entire synovial joint, including the cartilage, joint lining, and subchondral bone. OA causes pain, swelling, and stiffness, consequently hindering the patient's ability to perform their main daily activities, which often leads to social isolation and depression. Up till now, there is no cure for OA treatment options target either symptomatic relief (mainly pain) such as acetaminophen, glucosamine, chondroitin sulfate, and non-steroidal anti-inflammatory drugs (NSAIDs) or structure repair.

Probiotics are live and active microorganisms widely known as the gut's beneficial bacteria. They are taken to alter the GI flora and provide health benefits such as achieving optimal digestion and immunological function.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Masking Description

outcome assessors were blinded to participant data. the researcher coded patient data before analysis

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients (both sexes) aged above 18 years who met the American College of Rheumatology (ACR) clinical criteria for KOA \[7\] and had symptomatic OA of at least one knee (index knee).

Exclusion Criteria

  • Rheumatoid arthritis or other active generalized inflammatory comorbidities affecting the gastrointestinal tract (IBD, celiac disease)
  • Performed a total knee replacement on the affected knee or the waiting list for joint replacement
  • surgeries (such as gastric bypass) or Other concomitant injuries can override OA symptoms or interfere with physical activity.
  • Malabsorption disorders, systemic organ failure (liver, renal, cardiac)
  • Use corticosteroids with doses above 10 mg/day or Intra-articular injections during the previous 6 months.
  • Recent antibiotic treatment (i.e., \<2 months before the beginning of the study).
  • Pregnancy/breastfeeding
  • Participants who smoked more than 10 cigarettes per day were excluded.
  • Immunosuppressive treatment or impaired immune system
  • Chronic or acute diarrhea

Arms & Interventions

Control group

Other

OA patients will receive only standard of care

Intervention: Control (Drug)

probiotic group

Experimental

OA patients will receive probiotic supplements (2 times daily) added to the standard of care.

Intervention: Probiotic Formula (Drug)

Outcomes

Primary Outcomes

The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

Time Frame: 3 months

A self-administered measure used in assessing pain, stiffness, and function in OA patients

Visual Analogue Scale (VAS)

Time Frame: 3 months

A pain rating scale that represents the severity of symptoms from 0 "no symptoms" to 10 "very severe symptoms." The patient marks the line according to his/her perception of their current state.

Secondary Outcomes

  • The Knee Injury and Osteoarthritis Outcome Score (KOOS)(3 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Asmaa Abdelfattah Elsayed

Lecturer of clinical pharmacy

Beni-Suef University

Study Sites (1)

Loading locations...

Similar Trials